Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 Aug 1;19(8):e0307670. doi: 10.1371/journal.pone.0307670

Knowledge of Tuberculosis preventive treatment among people living with HIV: A cross-sectional survey in selected regions of Tanzania

Felix Christopher Alexander 1,*, Johnson Jeremia Mshiu 1, Anelisa Martin Rushaigo 1, Erick Josephat Mgina 2, Victor Enock Wiketye 3, Segere Chacha Mtundi 1, Sylvia Thomas Haule 1, Michael Kipenda Katende 1, Esther Manka Evarist 1, Luciana Charles Kapama 1, Aloisia Ibrahim Shemdoe 1, Charles Elias Makasi 1, Majaha Melkisedeck Lolakeha 1, Victor Kenedy Minja 1, Omary Abdallah Kimbute 1, Kunda John Stephen 1, Nyagosya Segere Range 1, Werner Meinrad Maokola 4, Bernard James Ngowi 1, Vitus Alberto Nyigo 1, Andrew Martin Kilale 1
Editor: Tinashe Mudzviti5
PMCID: PMC11293724  PMID: 39088461

Abstract

Background

Tuberculosis remains a significant global health concern, especially for People Living with HIV, who are at an increased risk of severe TB disease. Despite the availability of TB Preventive Treatment, knowledge gaps persist among People Living with HIV regarding its importance, accessibility, and administration. The study aimed to assess TPT knowledge levels and determinants among People Living with HIV in Tanzania.

Methods

A cross-sectional survey was conducted from April to May 2023 in 12 regions of mainland Tanzania. The study included PLHIV aged 18 years and above, receiving HIV care in selected Care and Treatment Centers. Data were collected through face-to-face interviews using a semi-structured questionnaire covering sociodemographic characteristics and Tuberculosis preventive treatment knowledge. Descriptive statistics, chi-square tests, and logistic regression analyses were employed for data analysis.

Results

Out of the 391 People Living with HIV interviewed, 71.4% demonstrated adequate Tuberculosis preventive treatment knowledge. Female participants, those attending urban health facilities, and individuals with longer durations of HIV care exhibited higher Tuberculosis preventive treatment knowledge levels. However, knowledge disparities persisted based on demographic characteristics such as gender and location of health facilities.

Conclusion

While a considerable portion of People Living with HIV demonstrated adequate higher Tuberculosis preventive treatment knowledge, addressing gaps among those with lower understanding is crucial. Targeted education campaigns tailored to the needs of People Living with HIV, especially in rural areas and among male populations, are essential. Collaborative efforts between national health programs and community organizations are vital to integrate Tuberculosis preventive treatment awareness effectively into comprehensive HIV care programs, ultimately reducing the burden of Tuberculosis among People Living with HIV and the general population.

Introduction

Tuberculosis is still a public health threat affecting a significant proportion of global populations particularly People Living with HIV (PLHIV) [1]. People living with HIV and children, especially those in the under-five age group are at an increased risk of severe forms of TB disease [2]. In 2022, TB claimed the lives of 1.3 million people worldwide, including 167,000 HIV-positive individuals [1]. As captured in data between the years 2020 through 2022, TB was the second most common infectious killer globally, after COVID-19, surpassing HIV and AIDS [3]. The World Health Organization’s 2030 End TB strategy recommends TB Preventive Treatment (TPT) for Individuals who potentially carry a TB infection or have been exposed to the bacterium who are more susceptible to developing TB compared to the general population. TPT is regarded as one of the most important public health interventions to prevent TB in both the community and individuals thus contributing to the broader goal of reducing the global burden of TB [4]

TB remains a significant comorbidity among PLHIV in Tanzania. In 2022, the proportion of people with TB coinfected with HIV stood at 17% [5]. The National TB and Leprosy Program (NTLP) adopted the WHO recommendations for TB prevention among high-risk populations thus recommending Daily Isoniazid as the main preventive drug for PLHIV and under-five household contacts of people with active TB. Being the most widely used TB preventive drug worldwide, with a low likelihood of drug-drug interactions, good tolerance, and much evidence of effectiveness, IPT has been shown to reduce mortality by 50% and more than 70% incidence among these populations in high TB-burden countries [6].

Knowledge of TB preventive treatment is a fundamental aspect of TB prevention among at-risk populations such as PLHIV. Education campaigns and outreach efforts are essential to ensure that accurate information reaches diverse populations, addressing disparities in knowledge and promoting a comprehensive approach to TB prevention. While evidence indicates a significant gap in IPT uptake in Tanzania [7], no studies have explored the knowledge of IPT treatment courses among PLHIV, despite its crucial role in promoting drug uptake. Similarly, rare studies have investigated this area in the Sub-Saharan region where TB prevention efforts are needed most. A study conducted in Southeast Nigeria revealed that about 60.5% of PLHIV had a lower level of IPT knowledge [8]

Tuberculosis-preventive drugs have evolved paving the way to shorter regimens compared to Isoniazid which is given daily for six months [4]. An important benefit of advancements in the pharmaceutical industry is the ability to significantly reduce the duration of TPT with certain medications such as rifampicin and rifapentine (rifamycin). The Ministry of Health (MoH) Tanzania is expected to roll out a shorter regimen of TB prevention service to extend its efforts in TB Prevention in the country by 2024. According to existing evidence, knowledge of the targeted populations on the treatment cascade is an important factor for its successful delivery and uptake. This study was conducted to assess the level and determinants of knowledge of IPT among PLHIV. The findings of this study will provide valuable insights to the NTLP and other stakeholders in the TB field, highlighting existing gaps and offering potential strategies to enhance awareness of TPT thereby promoting optimal health outcomes among the target populations.

Materials and methods

Study design

A health facility-based cross-sectional survey was conducted from April 2023 to May 2023.

Study area

The study was conducted in 12 regions of mainland Tanzania, namely, Dar es Salaam, Mara, Dodoma, Ruvuma, Tanga, Simiyu, Mbeya, Kagera, Mwanza, Shinyanga, Pwani, and Geita in mainland Tanzania. The regions are supported by the Global Fund to combat TB, HIV, and Malaria.

Study population

The study enrolled participants aged 18 years and above, who were receiving HIV care and treatment in CTCs in the study regions above.

Sample size and sampling procedure

The sample size for the study was obtained using a single proportion formula with the assumption that 50% of the PLHIV in the population are knowledgeable about IPT. An intra-class coefficient (ICC) of 0.01, a cluster size of 11, and an expected response rate of 99% meant the study was estimated to require a sample size of 427 for estimating the expected proportion with 5% absolute precision and 95% confidence. Thus, 39 clusters, each of 11 sizes were calculated to be selected for the study, and the list of all health facilities offering HIV care and treatment in each study region was obtained. A probability proportional to the size of PLHIV was used to select 39 health facilities in 12 regions. A systematic sampling procedure was used to select eleven PLHIV from selected facilities for the interview.

Data collection

Face-to-face interviews were conducted to gather data using a semi-structured questionnaire altered and modified from earlier research [8]. The questionnaire was designed and uploaded to a server located at the National Institute for Medical Research (NIMR), Muhimbili Centre. Later questionnaires were downloaded onto Android mobile devices using the Open Data Kit (ODK) application for data collection. The information collected included participants’ social demographic characteristics, duration of care, and knowledge of IPT.

Measurement of variables

In this study, knowledge regarding IPT was evaluated through a set of four questions, each accompanied by multiple-choice options. These questions aimed to assess participants’ comprehension of several crucial aspects: the preventive effectiveness of IPT against TB, awareness of where IPT services are accessible, understanding of the duration of IPT dose, and recognition of the specific demographic groups targeted for IPT administration. The score set ranged from 0 to 16, with a higher score indicating better knowledge and a lower score indicating poor knowledge. To categorize knowledge scores, a Bloom’s cut-off system was applied, following the methodology outlined by [9, 10]. Specifically, a cut-off of ≥ 60% was utilized to classify participants as having adequate knowledge of IPT.

Data analysis

Stata version 14.2 (Stata Corp, Texas-USA) was used for data management and statistical analysis. Descriptive statistics were employed to characterize participants’ sociodemographic profiles and their understanding of IPT. Bloom’s cut-off point was used to determine adequate knowledge (≥60%). Pearson’s chi-square test was utilized to assess the relationship between participants’ knowledge of IPT and their sociodemographic attributes. To accommodate potential clustering effects, a generalized linear mixed model was applied. In this model, knowledge served as the dependent variable, while sociodemographic characteristics were used as predictors. Odds Ratios were computed with a 95% confidence interval, and statistical significance was determined at p < 0.05.

Ethical consideration

Ethical clearance was secured from the National Health Research Ethics Committee (NatHREC) of the National Institute for Medical Research, with Certificate No. NIMR/HQ/R.8a/Vol IX/4256. Additionally, permission to conduct the study was obtained from relevant authorities in the selected regions, districts, and health facilities. Before each interview, participants were briefed on the study’s objectives and assured that participation was voluntary. Written consent was obtained from all participants before their involvement in the study.

Results

Description of study participants

A total of 391 PLHIV were interviewed. The majority of respondents 279(71.4%) were female, while males accounted for 112 (28.6%). In terms of age group, more than one-third 154(39.4%) were aged between 32–45 years, and more than quarter 121(30.9%) were aged between 46–59 years. The mean age was 44 years with a standard deviation of 12.7. Regarding marital status, nearly half of the respondents 186 (47.6%) were married, followed by those who were divorced, widowed, or separated 128 (32.7%), and single individuals 77 (19.7%). The educational background varied, with the majority 282 (72.1%) having completed primary education, followed by those with no formal education 59 (15.1%) (Table 1).

Table 1. Socio-demographic characteristics of respondents (n = 391).

Variable Frequency Percentage
Sex
    Male 112 28.6
    Female 279 71.4
Age group (years)
    18–31 65 16.6
    32–45 154 39.4
    46–59 121 30.9
    ≥60 51 13
Mean (SD) 44.0 12.7
Marital status
    Married 186 47.6
    Single 77 19.7
    Divorced/widowed/separated 128 32.7
Level of education
    No formal education 59 15.1
    Primary education 282 72.1
    Secondary education 41 10.5
    Certificate 5 1.3
    Diploma/University 4 1.0
Facility level
    Hospital 97 24.8
    Health Centre 183 46.8
    Dispensary 111 28.4
Facility ownership
    Public 323 82.6
    Faith-based 51 4.3
    Private 17 4.3
Occupation
    Unemployed 19 4.9
    employed 16 4.1
    Farmers 235 60.1
    Business 74 18.9
Location
    Urban 132 33.8
    Rural 259 66.2
Duration in HIV care
    Less than one year 52 13.3
    One year and above 339 86.7

Knowledge of IPT among PLHIV

A total of 391 PLHIV were interviewed to assess IPT knowledge. When asked about the effectiveness of IPT in preventing TB, a substantial percentage 188 (48.1%) responded affirmatively, while 121 (31%) expressed absolute confidence in the capacity of IPT to prevent TB disease. However, a notable portion of respondents, 60 (15.4%) were uncertain about IPT’s efficacy. In terms of access to IPT services, half of the respondent 196 (50.1%) knew where to access them, with 135 (34.5%) expressing absolute certainty. Regarding the understanding of the duration of IPT, 150 (38.4%) were aware of the recommended completion period, while 107 (27.4%) were certain. When asked about the target groups for IPT services, 114 (29.5%) did not know them, while 32 (8.2%) expressed absolute certainty (Table 2).

Table 2. Responses on IPT knowledge questions among participants (n = 391).

Variable Frequency Percentage (%)
Do you think IPT can prevent you from TB?
Absolutely No 17 4.35
No 5 1.3
Not sure 60 15.4
Yes 188 48.1
Absolutely Yes 121 31
Do you know where to get IPT services?
Absolutely No 10 2.6
No 26 6.7
Not sure 24 6.1
Yes 196 50.1
Absolutely Yes 135 34.5
Do you know how long the IPT dose takes?
Absolutely No 20 5.1
No 58 14.8
Not sure 56 14.3
Yes 150 38.4
Absolutely Yes 107 27.4
Do you know groups of people are targeted for IPT?
Absolutely No 37 9.5
No 114 29.5
Not sure 109 27.9
Yes 99 25.3
Absolutely Yes 32 8.2

Relationship between participants’ demographic characteristics and IPT knowledge level

A bivariate analysis was conducted to examine the relationship between participants’ knowledge levels and various demographic characteristics. Of the 391 participants, 279 (71.4%) demonstrated adequate knowledge. In terms of sex, a statistically significant association was observed (p<0.001), with 185 (78.4%) of females exhibiting adequate knowledge compared to 94 (60.6%) of males. Age groups did not show a significant association with knowledge (p = 0.348). Marital status did not show any significant association (p = 0.108), although divorced/widowed/separated individuals showed a higher percentage of adequate knowledge 100 (78.1%) compared to singles 51 (66.2%) and married participants 128 (68.8%). Residence was associated with knowledge p = 0.001, with urban facilities 177 (77.6%) having adequate knowledge compared to rural facilities 102 (62.6%). Duration in treatment and care center was also associated with knowledge p = 0.019 (Table 3).

Table 3. Bivariate analysis of the relationship between knowledge and demographic characteristics of participants (n = 391).

Variable Adequate knowledge n (%) Inadequate knowledge n (%) p-value
279(71.4) 112(28.6)
Sex
    Male 94(60.6) 61(39.4) <0.001
    Female 185(78.4) 51(21.6)
Age group (years)
    18–31 43(66.2) 22(33.8) 0.348
    32–45 111(72.1) 43(27.9)
    46–59 92(76.0) 29(24.0)
    ≥60 33(64.7) 18(35.3)
Marital status
    Single 51(66.2) 26(33.8) 0.108
    Married 128(68.8) 58(31.2)
    Divorced/widowed/separated 100(78.1) 28(21.9)
Level of education
    No formal education 41(66.1) 21(33.9) 0.553
    Primary education 206(72.8) 77(27.2)
    Secondary education 32(69.6) 14(30.4)
Facility level
    Hospital 70(72.2) 27(27.8) 0.951
    Health Centre 131(71.6) 52(28.4)
    Dispensary 78(70.3) 33(29.7)
Facility ownership
    Public 236(73.1) 87(26.9) 0.238
    Faith-based 10(58.8) 7(41.2)
    Private 33(64.7) 18(35.3)
Occupation
    Unemployed 24(68.6) 11(31.4) 0.803
    employed 25(69.4) 11(30.6)
    Farmers 168(70.6) 70(29.4)
    Business 62(75.6) 20(24.4)
Location
    Rural 102(62.6) 61(37.4) 0.001
    Urban 177(77.6) 51(22.4)
Distance from home to health facility
    Less than 2km 65(27.7) 170(72.3) 0.597
    2km and above 47(30.1) 109(69.9)
Duration in care and treatment center
    Less than one year 30(57.7) 22(42.3) 0.019
    One year and above 249(73.4) 90(26.6)  

Determinants of knowledge of IPT among PLHIV

The multivariable logistic regression analysis was used to examine the association between knowledge of TB prevention and various demographic characteristics among the participants. The adjusted odds ratios (AOR) and 95% confidence intervals (CI) were calculated for each variable. Female participants demonstrated a significantly higher likelihood of adequate knowledge compared to their male counterparts (AOR = 2.64, 95% CI: 1.36–5.15, p = 0.004). In terms of education, secondary education (AOR = 1.75, 95% CI: 1.00–3.08, p = 0.050) was associated with higher knowledge levels compared to those with no formal education. Participants from the urban location were two times (AOR = 2.28, 95% CI: 1.95–2.67, p <0.001) likely to have adequate knowledge as compared to participants from rural. Additionally, participants with one year and above in HIV care had higher odds of adequate knowledge (AOR = 2.24, 95% CI: 2.02–2.48, p < 0.001). The other variables, such as facility level, facility ownership, occupation, and distance from home, did not show significant associations with knowledge levels (Table 4).

Table 4. A multivariable logistic regression analysis showing the relationship between knowledge and demographic characteristics.

Variable AOR (95%CI) p-value
Sex
    Male 1
    Female 2.64(1.36–5.15) 0.004
Age group (years)
    18–31 1
    32–45 0.85(0.48–1.50) 0.572
    46 years and above 0.91(0.34–2.44) 0.851
Marital status
    Single 1
    Married 1.85(0.42–8.15) 0.416
    Divorced/widowed/separated 2.30(2.15–2.45) <0.001
Level of education
    No formal education 1
    Primary education 1.56(0.92–2.66) 0.101
    Secondary education 1.75(1.00–3.08) 0.050
Facility level
    Hospital 1
    Health Centre 0.83(0.40–1.74) 0.630
    Dispensary 0.93(0.63–1.35) 0.688
Facility ownership
    Public 1
    Private 0.41(0.17–1.01) 0.053
    Faith-based 0.60(0.14–2.61) 0.492
Occupation
    Unemployed 1
    employed 1.19(0.36–3.95) 0.782
    Farmers 1.13(0.60–2.11) 0.706
    Business 1.14(0.85–1.53) 0.375
Location
    Rural 1
    Urban 2.28(1.95–2.67) <0.001
Distance from home to health facility
    Less than 2km 1
    2km and above 0.68(0.56–0.83) <0.001
Duration in care and treatment centers
    Less than one year 1
    One year and above 2.24(2.02–2.48) <0.001

Discussion

The findings of this study show that more than a third of PLHIV demonstrated an overall adequate knowledge of IPT. These findings differed from a similar study conducted in South East Nigeria [8] which found an overall lower knowledge level of 39.5%. The variance in knowledge levels may be attributed to temporal factors suggesting potential shifts in awareness over time because the Nigerian study was conducted in 2018 while the current study was conducted in 2023. Moreover, the geographical as well as social and political differences in the study populations may account for the recorded difference as the former study was conducted in Western parts of Africa while this one comes from the Eastern part.

The observed level of TPT knowledge in the study implies success in adapting the WHO recommendation for enhancing knowledge of TPT among PLHIV as a key intervention to reduce the socioeconomic burden of active TB on PLHIV and the general population [11]. Regarding the determinants of knowledge, our study found that being female, attending an urban-based health facility for IPT services, and being on HIV care for more than a year were important factors influencing knowledge of IPT among PLHIV.

A significant association between gender and TPT knowledge was observed. Specifically, female participants were identified as being more than two times more likely to have adequate TPT knowledge compared to their male counterparts. These findings conform with the study conducted in Nigeria [8] and Ethiopia [12] which all together reported that female participants had adequate IPT knowledge compared to male participants. These findings suggest that there may be gender-specific factors, such as differences in healthcare-seeking behavior, awareness, or health education exposure influencing the level of knowledge among PLHIV about TPT. Understanding these gender-related disparities is crucial for the development of targeted interventions to enhance TPT knowledge, ensuring that both male and female populations receive adequate information and education about preventive therapy for TB.

The current study revealed that the location of a health facility was significantly associated with the level of knowledge on IPT among PLHIV. We found that PLHIV who received IPT care from urban facilities were more than twice as likely to have sufficient IPT knowledge compared to those receiving care in rural health facilities. These findings suggest that there may be factors related to the urban setting, such as better access to information, communication channels, and educational resources [9] which may contribute to a higher level of IPT knowledge among PLHIV from urban locations. The NTPs and other TB control stakeholders have a critical task in implementing targeted interventions on awareness campaigns in rural areas. These locations require such interventions the most to address the urban-rural knowledge disparities among PLHIV particularly on TB preventive treatment.

The study revealed that duration of care was an important factor for knowledge of IPT among PLHIV. We found that participants who had longer than a year of HIV care had an adequate level of knowledge of IPT compared to those who had just joined HIV care. These findings concur with the findings of a study conducted in Ethiopia which found that PLHIV who were on care for longer than six months were more than two times likely to be informed about IPT compared to those who had less than six months on care [12]. It is important to note that this association could be attributed to several factors including longer durations of interactions with healthcare providers and participation in health education sessions during HIV treatment. Additionally, individuals who have been in HIV care for an extended duration may have had more exposure to informational materials, counseling, and awareness campaigns, leading to a better understanding of IPT.

Conclusion

While a substantial portion of PLHIV demonstrated an overall adequate knowledge of IPT, the significance of addressing IPT knowledge gaps among PLHIV who were found to have low levels of knowledge cannot be underestimated. These findings underscore the importance of ongoing education and awareness campaigns to ensure that PLHIV has accurate and comprehensive knowledge about TPT. Additionally, the study highlights the significance of demographic factors such as gender, location of health facilities, and duration of HIV care, which influence IPT knowledge among PLHIV. Addressing these determinants through targeted interventions can contribute to improving health outcomes and ultimately reducing the burden of TB among PLHIV and the general population. It is crucial to foster collaboration between the NTLP, The National AIDS, STIs, and Hepatitis Control Program (NASHCoP), and community organizations to integrate TPT awareness interventions into comprehensive HIV care programs, enhancing their reach and effectiveness among PLHIV.

Study limitations

The study regions were selected based on the funder’s area of support. This sampling may limit the country-wide generalizability of the results of this study. Despite our efforts, logistical challenges during data collection hindered us from reaching the desired sample size within the allocated timeframe.

Acknowledgments

We sincerely acknowledge the support from the District TB coordinators from study regions and the cooperation we received from data clacks at Care and Treatment Clinics whose contribution significantly impacted the success of this work.

Data Availability

All data files are available from the figshare repository. DOI: 10.6084/m9.figshare.25408066.

Funding Statement

Our study received funding support from the Global Fund to fight against HIV, TB and Malaria in Tanzania through the NASHCoP. However, the funder did not take part in the study design, data collection and analysis, decision to publish, nor preparation of this manuscript. AMK received the fund. https://www.theglobalfund.org/en/results/.

References

  • 1.WHO. Tuberculosis. 2023. [cited 28 Jan 2024]. Available: https://www.who.int/news-room/fact-sheets/detail/tuberculosis [Google Scholar]
  • 2.WHO. HIV and AIDS. 2023. [cited 13 Feb 2024]. Available: https://www.who.int/news-room/fact-sheets/detail/hiv-aids?gclid=Cj0KCQiAoKeuBhCoARIsAB4WxtegyTYr7CG_IB22XXSjse4asduDwyV4f6yuxxpGRVLNGtiCGdyJUQgaArGdEALw_wcB [Google Scholar]
  • 3.WHO. FACT SHEET. 2023.
  • 4.WHO. TPT FAQ. 2020.
  • 5.NTLP. Report of the Tanzania Mid-Term Review of the National Tuberculosis and Leprosy Program Strategic Plan VI, 2020–2025. 2023.
  • 6.Hunter Olivia F. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania. BMC Infect Dis. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Manisha H, Amani W, Garrib A, Senkoro M, Mfinanga S. IPT coverage and determinants of care coverage in Tanzania. Public Health Action. 2022;12: 141. doi: 10.5588/pha.22.0018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Akamike IC, Okedo-Alex IN, Agu AP, Alo C, Ogbonnaya LU. Knowledge and adherence to isoniazid preventive therapy among people living with HIV in multilevel health facilities in South-East, Nigeria: baseline findings from a quasi-experimental study. Pan Afr Med J. 2020;36: 1–10. doi: 10.11604/PAMJ.2020.36.261.22496 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kazaura M, Kamazima SR. Knowledge, attitudes and practices on tuberculosis infection prevention and associated factors among rural and urban adults in northeast Tanzania: A cross-sectional study. PLOS Global Public Health. 2021;1: e0000104. doi: 10.1371/journal.pgph.0000104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Olum R, Chekwech G, Wekha G, Nassozi DR, Bongomin F. Coronavirus Disease-2019: Knowledge, Attitude, and Practices of Health Care Workers at Makerere University Teaching Hospitals, Uganda. Front Public Health. 2020;8. doi: 10.3389/fpubh.2020.00181 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Malhotra Bandana, World Health Organization. Department of HIV/AIDS., Stop TB Initiative (World Health Organization). Guidelines for intensified tuberculosis case-finding and isoniazid preventative therapy for people living with HIV in resource-constrained settings. 2011.
  • 12.Wesen A, Mitike G. Provision and awareness for isoniazid preventive therapy among PLHIV in Addis Ababa, Ethiopia. BMC Int Health Hum Rights. 2012;12: 2. doi: 10.1186/1472-698X-12-2 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Tinashe Mudzviti

13 May 2024

PONE-D-24-10620Knowledge of Tuberculosis Preventive Treatment among People Living with HIV: A cross-sectional survey in selected regions of TanzaniaPLOS ONE

Dear Dr. Alexander,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf"

2. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

"This study received funding support from the Global Fund through NASHCoP of the Ministry of Health 

Tanzani"

We note that you have provided funding information that is currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"Our study received funding support from the Global Fund to fight against HIV, TB and Malaria in Tanzania through the NASHCoP. However, the funder did not take part in the study design, data collection and analysis, decision to publish, nor preparation of this manuscript.

AMK received the fund. 

 https://www.theglobalfund.org/en/results/ "

Please include your amended statements within your cover letter; we will change the online submission form on your behalf."""

3. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

Additional Editor Comments:

The authors have presented a paper evaluating the knowledge of TPT among PLWHIV in Tanzania.

Major comments

1. The calculated sample size for this study is 427 and the number of participants enrolled was 391. Not meeting the sample size means the results lack statistical power.

2. Another important factor to consider when evaluating knowledge about TPT is, "Time since enrolling into care" It is likely that those who have been in care longer and those who have actually received the TPT will be more knowledgeable. This variable needs to be evaluated.

3. There needs to be stronger justification by the authors why they think that PLWHIV should be knowledgeable about TPT. Patients do not prescribe this modality to themselves so knowledge about TPT is the purview of healthcare workers and not individuals that have received a diagnosis of HIV.

Minor comments

1. Consider having the paper reviewed for grammar. There are some grammatical errors that need to be corrected e.g. line 67, "Daily" should be, "daily" line 87, "Prevention" should be, "prevention"

2. Line 113: Define the abbreviation CTC in the paper before using it.

3. IPT and TPT cannot be used interchangeably. This paper evaluated IPT knowledge. IPT is a strategy for TPT. So, the title is not precise because it refers to TPT while the study evaluated IPT. Therefore even in the paper, the use of the acronym TPT has to be precise: line 117 and page 15 of the paper.

4. In line 142 please state who (9) and (10) are then reference them.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Comments to the Author

Reviewer #1: An interesting and, in the context of the authors' country, an important study has been conducted.

I have a few major questions that I would like to clarify:

• The manuscript lacks context about the TB and HIV situation in Tanzania. In lines 65-66 it is written "In 2022, the proportion of people with TB coinfected with HIV stood at 17%". Regarding this study, much more important information would be what proportion of HIV-infected persons have (had) active TB and what proportion of HIV-infected persons have latent TB infection?

• The authors do not mention anywhere the prevalence of latent TB infection and its diagnosis in Tanzania. Preventive treatment is given in the case of latent TB infection. Clarity is needed.

• In lines 66-69, the statement "The National TB and Leprosy Program (NTLP) adopted the WHO recommendations for TB prevention among high-risk populations thus recommending daily Isoniazid as the main preventive drug for PLHIV and under-five household contacts of people with active TB "unclear. Different situations are discussed in one sentence - HIV infection (with latent TB infection) and contact persons with a patient with active TB. Need to clarify.

Minor concerns:

• In line 70, the abbreviation ISP is not expanded.

• In line 14 is probably misspelled "Tanzani".

Reviewer #2: This study examines knowledge of TB preventive treatment among a sample of people living with HIV in Tanzania. Overall, the study was very well written and easy to understand. The study findings were presented in a clear way and all tables were well structured and easy to interpret. The study discusses an important topic in HIV prevention, and the authors give plausible explanations of the key determinants of TPT knowledge that their study identified (e.g., gender, location etc). I have no additional comments. The paper was well written and it successfully addressed its central questions.

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

==============================

Please submit your revised manuscript by 25 May 2024. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Tinashe Mudzviti, MPhil(MD)

Academic Editor

PLOS ONE

PLoS One. 2024 Aug 1;19(8):e0307670. doi: 10.1371/journal.pone.0307670.r002

Author response to Decision Letter 0


23 May 2024

'When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process'

I received this from the editor, but I had from the previous submission made the data available in Frig share and attached the Doi: . The data freely accessible and I ticked

Attachment

Submitted filename: Response to Reviewers.docx

pone.0307670.s001.docx (20.2KB, docx)

Decision Letter 1

Tinashe Mudzviti

19 Jun 2024

PONE-D-24-10620R1Knowledge of Tuberculosis preventive treatment among people living with HIV: A cross-sectional survey in selected regions of TanzaniaPLOS ONE

Dear Dr. Alexander,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:  Authors need to include the limitation in the manuscript that there is a reduction in the power of the results which was a result of not meeting the sample size.

==============================

Please submit your revised manuscript by Aug 03 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Tinashe Mudzviti, MPhil(MD)

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Aug 1;19(8):e0307670. doi: 10.1371/journal.pone.0307670.r004

Author response to Decision Letter 1


26 Jun 2024

I have attached my response on the study limitations which made us fail to reach the sample size.

Attachment

Submitted filename: Response to Reviewers.docx

pone.0307670.s002.docx (13.1KB, docx)

Decision Letter 2

Tinashe Mudzviti

10 Jul 2024

Knowledge of Tuberculosis preventive treatment among people living with HIV: A cross-sectional survey in selected regions of Tanzania

PONE-D-24-10620R2

Dear Dr. Alexander,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Tinashe Mudzviti, MPhil(MD)

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Tinashe Mudzviti

24 Jul 2024

PONE-D-24-10620R2

PLOS ONE

Dear Dr. Alexander,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Tinashe Mudzviti

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0307670.s001.docx (20.2KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0307670.s002.docx (13.1KB, docx)

    Data Availability Statement

    All data files are available from the figshare repository. DOI: 10.6084/m9.figshare.25408066.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES